MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis

Cited by (499)

Items 101–200 of 499

1. Emerging Targets in Non-Small Cell Lung Cancer
   Louisa Liu, Joshua Soler, Karen L. Reckamp, K. Nathan Sankar · 2024 · International Journal of Molecular Sciences
2. The Atypical Kinase RIOK1 Promotes Tumor Growth and Invasive Behavior
   Florian Weinberg, Nadine Reischmann, Lisa Fauth, Sanaz Taromi, Justin Mastroianni, M. Köhler, Sebastian Halbach, Andrea C. Becker, Niantao Deng, Tatjana Schmitz et al. · 2017 · EBioMedicine
3. Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors
   Hong Lin, Juan I. Luengo · 2019 · Bioorganic & Medicinal Chemistry Letters
4. Protein arginine methyltransferase 5: a potential cancer therapeutic target
   Yuanyang Yuan, Hong Nie · 2021 · Cellular Oncology
5. All is not lost: learning from 9p21 loss in cancer
   Pavlina Spiliopoulou, S.Y. Cindy Yang, Jeff P. Bruce, Ben X. Wang, Hal K. Berman, Trevor J. Pugh, Lillian L. Siu · 2022 · Trends in Immunology
6. Systematic profiling of conditional degron tag technologies for target validation studies
   Daniel P. Bondeson, Zachary Mullin-Bernstein, Sydney Oliver, Thomas A. Skipper, Thomas C. Atack, Nolan R. Bick, Meilani Ching, Andrew A. Guirguis, Jason J. Kwon, Carly R. Langan et al. · 2022 · Nature Communications
7. Medicinal chemistry strategies targeting PRMT5 for cancer therapy
   Siyu Fu, Qinwen Zheng, Dan Zhang, Congcong Lin, Liang Ouyang, Jifa Zhang, Lei Chen · 2022 · European Journal of Medicinal Chemistry
8. Chemical Inhibition of Protein Methyltransferases
   Matthieu Schapira · 2016 · Cell chemical biology
9. Drug Discovery and Chemical Biology of Cancer Epigenetics
   Scott A. Ribich, Darren M. Harvey, Robert A. Copeland · 2017 · Cell chemical biology
10. Integrative analysis of large-scale loss-of-function screens identifies robust cancer-associated genetic interactions
    Christopher J. Lord, Niall Quinn, Colm J. Ryan · 2020 · eLife
11. PRMT5: a putative oncogene and therapeutic target in prostate cancer
    Elena Beketova, Jake L. Owens, Andrew Michael Asberry, Chang‐Deng Hu · 2021 · Cancer Gene Therapy
12. Metabolic Rewiring and Redox Alterations in Malignant Pleural Mesothelioma
    Urso, Loredana, Cavallari, Ilaria, Sharova, Evgeniya, Ciccarese, Francesco, Pasello, Giulia, Ciminale, Vincenzo · 2020 · British Journal of Cancer
13. Targeting the methionine−methionine adenosyl transferase 2A−S-adenosyl methionine axis for cancer therapy
    Jiamin Guo, Yanzhong Yang, Ralf Buettner, Steven T. Rosen · 2022 · Current Opinion in Oncology
14. Phospholipase D and Choline Metabolism
    Fredrick O. Onono, Andrew J. Morris · 2019 · Handbook of experimental pharmacology
15. Next-generation therapies for pancreatic cancer
    Conor W. Buckley, Eileen Mary O'Reilly · 2024 · Expert Review of Gastroenterology & Hepatology
16. Evaluation of MTAP and p16 immunohistochemical deficiency as surrogate marker for CDKN2A/B homozygous deletion in gliomas
    Theoni Maragkou, Stefan Reinhard, Patric Jungo, Baptiste Pasquier, Maja Neuenschwander, Philippe Schucht, Erik Vassella, Ekkehard Hewer · 2023 · Pathology
17. Non-Histone Protein Methylation: Biological Significance and Bioengineering Potential
    Roberto Di Blasi, Oleg B. Blyuss, John F. Timms, Daniel Conole, Francesca Ceroni, Harry J. Whitwell · 2021 · ACS Chemical Biology
18. Protein Arginine Methylation: An Emerging Modification in Cancer Immunity and Immunotherapy
    Weijing Dai, Jian‐Guo Zhang, Siqi Li, Fajian He, Qiao Liu, Jun Gong, Zetian Yang, Yan Qing Gong, Fang Tang, Zhihao Wang et al. · 2022 · Frontiers in Immunology
19. Leveraging Structure-Based Drug Design to Identify Next-Generation MAT2A Inhibitors, Including Brain-Penetrant and Peripherally Efficacious Leads
    Mingzong Li, Zenon D. Konteatis, Nelamangala V. Nagaraja, Yue Chen, Shubao Zhou, Guangning Ma, Stefan Größ, Katya Marjon, Marc L. Hyer, Everton Mandley et al. · 2022 · Journal of Medicinal Chemistry
20. Targeting Protein Arginine Methyltransferase 5 in Disease
    André Richters · 2017 · Future Medicinal Chemistry
21. SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls melanoma growth
    Hironari Tamiya, Hyungsoo Kim, Oleksiy Klymenko, Heejung Kim, Yongmei Feng, Tongwu Zhang, Ji Yun Han, Ayako Murao, Scott J. Snipas, Lucia B. Jilaveanu et al. · 2017 · Journal of Clinical Investigation
22. Fragment-Based Design of a Potent MAT2a Inhibitor and in Vivo Evaluation in an MTAP Null Xenograft Model
    Claudia De Fusco, Marianne Schimpl, Ulf Börjesson, Tony Cheung, Iain T. Collie, Laura Evans, Priyanka Narasimhan, Christopher J. Stubbs, Mercedes Vázquez–Chantada, David J. Wagner et al. · 2021 · Journal of Medicinal Chemistry
23. The Influence of Arginine Methylation in Immunity and Inflammation
    Nivine Srour, Sarah Khan, Stéphane Richard · 2022 · Journal of Inflammation Research
24. Combined inhibition of MTAP and MAT2a mimics synthetic lethality in tumor models via PRMT5 inhibition
    Gabriel T. Bedard, Nord Gilaj, Karina Peregrina, Isabella Brew, Elena Tosti, Karl J. Shaffer, Peter C. Tyler, Winfried Edelmann, Leonard H. Augenlicht, Vern L. Schramm · 2023 · Journal of Biological Chemistry
25. Genetic, epigenetic and genomic mechanisms of methionine dependency of cancer and tumor-initiating cells: What could we learn from folate and methionine cycles
    Jean‐Louis Guéant, Abderrahim Oussalah, Racha Zgheib, Youssef Siblini, Shyue-Fang Battaglia-Hsu, Farès Namour · 2020 · Biochimie
26. The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer
    Ryan V. Quiroz, Michael H. Reutershan, Sebastian E. Schneider, David L. Sloman, Brian M. Lacey, Brooke M. Swalm, Charles See Yeung, Craig R. Gibeau, Daniel S. Spellman, Danica A. Rankic et al. · 2021 · Journal of Medicinal Chemistry
27. Mechanisms Governing Metabolic Heterogeneity in Breast Cancer and Other Tumors
    Sayani Patra, Naveed Elahi, Aaron Armorer, Swathi Arunachalam, Joshua Omala, Iman Hamid, Anthony W. Ashton, David A. Joyce, Xuanmao Jiao, Richard G. Pestell · 2021 · Frontiers in Oncology
28. Targeting allosteric regulation of cancer metabolism
    Daniel M. Kremer, Costas Andreas Lyssiotis · 2022 · Nature Chemical Biology
29. Genomic landscape of non‐small‐cell lung cancer with methylthioadenosine phosphorylase ( MTAP ) deficiency
    Prashanth Ashok Kumar, Stephen L. Graziano, Natalie A. Danziger, Dean C. Pavlick, Eric Allan Severson, Shakti H Ramkissoon, Richard S.P. Huang, Brennan James Decker, Jeffrey S. Ross · 2022 · Cancer Medicine
30. Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers
    Natalie Y.L. Ngoi, Tin‐Yun Tang, Catia Fava Gaspar, Dean C. Pavlick, Gregory M. Buchold, Emma L. Scholefield, Vamsi Parimi, Richard S.P. Huang, Tyler Janovitz, Natalie A. Danziger et al. · 2024 · The Oncologist
31. The PAF complex regulation of Prmt5 facilitates the progression and maintenance of MLL fusion leukemia
    Justin Serio, James P. Ropa, Wei Chen, Maria Mysliwski, Nirmalya Saha, L Chen, Jingya Wang, Hongzhi Z. Miao, Tomasz Cierpicki, Jolanta E. Grembecka et al. · 2017 · Oncogene
32. Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations
    Yuxuan Che, Yang Liu, Yixin Yao, Holly Ann Hill, Yijing Li, Qingsong Cai, Fangfang Yan, Preetesh Jain, Wei Wang, Lixin Rui et al. · 2023 · Blood Cancer Journal
33. PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies
    Jack Carter, Michael Hulse, Monisha Sivakumar, Jessica Burtell, Venkat Thodima, Min Wang, Anjana Agarwal, Komali Vykuntam, Jacob Spruance, Neha Bhagwat et al. · 2023 · Cancer Research Communications
34. Targeting cancer's metabolic co-dependencies: A landscape shaped by genotype and tissue context
    Junfeng Bi, Sihan Wu, Wenjing Zhang, Paul S. Mischel · 2018 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
35. BRAF V600E mutation and 9p21: CDKN2A/B and MTAP co-deletions - Markers in the clinical stratification of pediatric gliomas
    Laura Frazão, Maria do Carmo Martins, Vasco Moura Nunes, José Pimentel, Cláudia C. Faria, José Miguéns, Amets Sagarribay, Mário Matos, Duarte Salgado, Sofia Nunes et al. · 2018 · BMC Cancer
36. Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities
    Sakti Chakrabarti, Mandana Kamgar, Amit Mahipal · 2022 · Cancers
37. Methylthioadenosine phosphorylase deficiency in tumors: A compelling therapeutic target
    Na Fan, Yi Zhang, Suyun Zou · 2023 · Frontiers in Cell and Developmental Biology
38. Small molecule targeting of chromatin writers in cancer
    Andrew R. Conery, Jennifer L. Rocnik, Patrick Trojer · 2021 · Nature Chemical Biology
39. The potential and challenges of targeting MTAP-negative cancers beyond synthetic lethality
    Chandler Bray, Cristina Domingo Balcells, Iain A. McNeish, Hector C. Keun · 2023 · Frontiers in Oncology
40. Nutrient availability shapes methionine metabolism in p16/ MTAP -deleted cells
    Sydney M. Sanderson, Peter G. Mikhael, Vijyendra Ramesh, Ziwei Dai, Jason W. Locasale · 2019 · Science Advances
41. Structure-Aided Design, Synthesis, and Biological Evaluation of Potent and Selective Non-Nucleoside Inhibitors Targeting Protein Arginine Methyltransferase 5
    Deqin Rong, Kaixin Zhou, Wei Fang, Hong Jun Yang, Yi Zhang, Qiongyu Shi, Yuting Huang, Jiayi Li, Hui Fen Dong, Lanlan Li et al. · 2022 · Journal of Medicinal Chemistry
42. Design and Structural Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High In Vivo Potency and Oral Bioavailability
    Silong Zhang, Luolong Qing, Ziwei Wang, Yu Zhang, Yuanyuan Li, Huaxiang Fang, Yi Liu, Huan He · 2023 · Journal of Medicinal Chemistry
43. TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers
    Kimberly J. Briggs, Kevin M. Cottrell, Matthew R. Tonini, Alice Tsai, Minjie Zhang, Douglas A. Whittington, Wenhai Zhang, Steven A. Lombardo, Satoshi Yoda, Erik Wilker et al. · 2025 · Translational Oncology
44. Pan-cancer clinical and molecular landscape of MTAP deletion in nationwide and international comprehensive genomic data
    Hiroaki Ikushima, Kousuke Watanabe, Aya Shinozaki‐Ushiku, Katsutoshi Oda, Hidenori Kage · 2025 · ESMO Open
45. Specific Targeting of MTAP -Deleted Tumors with a Combination of 2′-Fluoroadenine and 5′-Methylthioadenosine
    Baiqing Tang, Hyung‐Ok Lee, Serim S. An, Kathy Qi Cai, Warren D. Kruger · 2018 · Cancer Research
46. Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma
    Marcelo Lima Ribeiro, Diana Reyes-Garau, Marc Armengol, Miranda Fernández-Serrano, Gaël Roué · 2019 · Frontiers in Genetics
47. Perturbation of Methionine/S-adenosylmethionine Metabolism as a Novel Vulnerability in MLL Rearranged Leukemia
    Aditya Barve, Alexis A. Vega, Parag P. Shah, Smita S. Ghare, Lavona K. Casson, Mark Wunderlich, Leah J. Siskind, Levi J. Beverly · 2019 · Cells
48. Selective PRMT5 Inhibitors Suppress Human CD8+ T Cells by Upregulation of p53 and Impairment of the AKT Pathway Similar to the Tumor Metabolite MTA
    Carolin Dorothea Strobl, Stefanie Schaffer, Tabea Haug, Simon Völkl, Katrin Peter, Katrin Singer, Martin Böttcher, Dimitrios Mougiakakos, Andréas Mackensen, Michael Aigner · 2019 · Molecular Cancer Therapeutics
49. PRMT5 silencing selectively affects MTAP‐deleted mesothelioma: In vitro evidence of a novel promising approach
    Marcella Barbarino, Daniele Cesari, Maria Bottaro, Luca Luzzi, Asadoor Amirkhani Namagerdi, Franca Maria Bertolino, Cristiana Bellan, Fabrizio Proietti, Pasquale Somma, Mariacarolina Micheli et al. · 2020 · Journal of Cellular and Molecular Medicine
50. Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype
    Felix Orben, Katharina Lankes, Christian Schneeweis, Zonera Hassan, Hannah Jakubowsky, Lukas Krauß, Fabio Boniolo, Carolin Schneider, Arlett Schäfer, Janine Murr et al. · 2022 · JCI Insight
51. Cancer Dependencies: PRMT5 and MAT2A in MTAP/p16-Deleted Cancers
    Katya Marjon, Peter Kalev, Kevin M. Marks · 2020 · Annual Review of Cancer Biology
52. Genomics-guided pre-clinical development of cancer therapies
    Hayley E. Francies, Ultan McDermott, Mathew J. Garnett · 2020 · Nature Cancer
53. PRMT5 regulates cell pyroptosis by silencing CASP1 in multiple myeloma
    Tian Xia, Ming Liu, Quan Zhao, Jian Ouyang, Peipei Xu, Bing Chen · 2021 · Cell Death and Disease
54. Simplifying the B Complex: How Vitamins B6 and B9 Modulate One Carbon Metabolism in Cancer and Beyond
    Carolina N. Franco, Laurence J. Seabrook, Steven T. Nguyen, Jack T. Leonard, Lauren Veronica Albrecht · 2022 · Metabolites
55. MTAP loss: a possible therapeutic approach for glioblastoma
    C. Pawan K. Patro, Nupur Biswas, Sandeep C. Pingle, Lin Feng, Misa Anekoji, L. Jones, Santosh Kesari, Feng Wang, Shashaanka Ashili · 2022 · Journal of Translational Medicine
56. Multifaceted WNT Signaling at the Crossroads Between Epithelial-Mesenchymal Transition and Autophagy in Glioblastoma
    Bárbara Paranhos Coelho, Camila Felix de Lima Fernandes, Jacqueline Marcia Boccacino, Maria Clara da Silva Souza, Maria Isabel Melo-Escobar, Rodrigo Nunes Alves, Mariana Brandão Prado, Rebeca Piatniczka Iglesia, Giovanni Cangiano, Giulia La Rocca Mazzaro et al. · 2020 · Frontiers in Oncology
57. Discovery of synthetic lethal interactions from large-scale pan-cancer perturbation screens
    Sumana Srivatsa, Hesam Montazeri, Gaia Bianco, Mairene Coto‐Llerena, Mattia Marinucci, Charlotte K.Y. Ng, Salvatore Piscuoglio, Niko Beerenwinkel · 2022 · Nature Communications
58. Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter’s transformation
    Zachary A. Hing, Janek S. Walker, Ethan C. Whipp, Lindsey T. Brinton, Matthew J. Cannon, Pu Zhang, Steven Sher, Casey B. Cempre, Fiona Brown-Burke, Porsha L. Smith et al. · 2023 · Nature Communications
59. PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition
    Yang Li, Lacey Elizabeth Dobrolecki, Christina Sallas, Xudong Zhang, Travis D. Kerr, Deepa Bisht, Yalong Wang, Sharad Awasthi, Babita Kaundal, Siqi Wu et al. · 2023 · Cell Reports Medicine
60. PRMT5: An Emerging Target for Pancreatic Adenocarcinoma
    Michael K.C. Lee, Sean Michael Grimmond, Grant A. McArthur, Karen E. Sheppard · 2021 · Cancers
61. Targeting the methionine addiction of cancer.
    Joni C Sedillo, Vincent L. Cryns · 2022 · PubMed Central
62. PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma
    Shelby L. Sloan, Fiona Brown-Burke, Mackenzie Long, Christoph Weigel, Shirsha Koirala, Ji-Hyun Chung, Betsy A. Pray, Lynda Villagomez, Claire Hinterschied, Anuvrat Sircar et al. · 2023 · Blood
63. MTAP as an emerging biomarker in thoracic malignancies
    Magdalena M. Brune, Spasenija Savic Prince, Tatjana Vlajnic, Obinna Chijioke, Luca Roma, David König, Lukas Bubendorf · 2024 · Lung Cancer
64. M-TAP Dance: Targeting PRMT1 and PRMT5 Family Members to Push Cancer Cells Over the Edge
    Nivine Srour, Sofiane Yacine Mersaoui, Stéphane Richard · 2019 · Cancer Cell
65. SERS analysis of cancer cell-secreted purines reveals a unique paracrine crosstalk in MTAP-deficient tumors
    Pablo S. Valera, Javier Plou, Isabel Garcı́a, Ianire Astobiza, Cristina Viera, Ana María Aransay, Jose‐Ezequiel Martín, Ivan R. Sasselli, Arkaitz Carracedo, Luis M. Liz‐Marzán · 2023 · Proceedings of the National Academy of Sciences
66. Discovery and In Vivo Efficacy of AZ-PRMT5i-1, a Novel PRMT5 Inhibitor with High MTA Cooperativity
    James M. Smith, Bernard C. Barlaam, David Beattie, Lauren Bradshaw, Ho Man Chan, Elisabetta Chiarparin, Olga Collingwood, Sophie L. Cooke, Anna S. Cronin, Iain A. Cumming et al. · 2024 · Journal of Medicinal Chemistry
67. Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel Opportunities
    Michael S. Lee, Shubham Pant · 2021 · American Society of Clinical Oncology Educational Book
68. Cancer synthetic vulnerabilities to protein arginine methyltransferase inhibitors
    Ernesto Guccione, Megan Catherine Schwarz, Federico Di Tullio, Slim Mzoughi · 2021 · Current Opinion in Pharmacology
69. Next-Generation Sequencing Reveals Potential Predictive Biomarkers and Targets of Therapy for Urothelial Carcinoma in Situ of the Urinary Bladder
    Stefan Garczyk, Nadina Ortiz‐Brüchle, Ursula Schneider, Isabella Lurje, Karolína Guricová, Nadine Therese Gaisa, Eva Lorsy, Katharina Lindemann-Docter, Axel Heidenreich, Ruth Knüchel · 2019 · American Journal Of Pathology
70. MTAP deficiency contributes to immune landscape remodelling and tumour evasion
    Wen‐Hsin Chang, Ssu‐Wei Hsu, Jun Zhang, Ji‐Min Li, David C.H. Yang, Chih‐Wei Chu, Estelle Heerim Yoo, Weici Zhang, Sung‐Liang Yu, Ching‐Hsien Chen · 2022 · Immunology
71. The biological essence of synthetic lethality: Bringing new opportunities for cancer therapy
    Meiyi Ge, Jian Luo, Yi Wu, Guobo Shen, Xi Kuang · 2024 · MedComm – Oncology
72. Patterns of Aneuploidy and Signaling Consequences in Cancer
    Nadja Zhakula-Kostadinova, Alison Marie Taylor · 2024 · Cancer Research
73. Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP -Deleted Cancers
    Liping H. Pettus, Matthew P. Bourbeau, Nuria A. Tamayo, Albert K. Amegadzie, Diane Beylkin, Shon K. Booker, John Butler, Michael J. Frohn, Matthew R. Kaller, Todd J. Kohn et al. · 2025 · Journal of Medicinal Chemistry
74. Synthetic essentiality: Targeting tumor suppressor deficiencies in cancer
    Di Zhao, Ronald Anthony DePinho · 2017 · BioEssays
75. Adverse histology, homozygous loss of CDKN2A/B, and complex genomic alterations in locally advanced/metastatic renal mucinous tubular and spindle cell carcinoma
    Chen Yang, Robert Cimera, Ruth Aryeequaye, Gowtham Jayakumaran, Judy Sarungbam, Hikmat A Al‐Ahmadie, Anuradha Gopalan, Sahussapont Joseph Sirintrapun, Samson W. Fine, Satish K. Tickoo et al. · 2020 · Modern Pathology
76. Whole-Exome Profiling of NSCLC Among African Americans
    Rony F. Arauz, Jung S. Byun, Mayank Tandon, Sanju Sinha, Skyler A. Kuhn, Sheryse Taylor, Adriana Zingone, Khadijah A. Mitchell, Sharon R. Pine, Kevin L Gardner et al. · 2020 · Journal of Thoracic Oncology
77. MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors
    Si Chen, Jiakai Hou, Roshni Jaffery, Ashley M. Guerrero, Rongjie Fu, Leilei Shi, Ningbo Zheng, Ritu Bohat, Nicholas A. Egan, Cheng‐Tai Yu et al. · 2024 · Journal for ImmunoTherapy of Cancer
78. Metabolic analysis reveals evidence for branched chain amino acid catabolism crosstalk and the potential for improved treatment of organic acidurias
    Stephen McCalley, David A. Pirman, Michelle F. Clasquin, Kendall R. Johnson, Shengfang Jin, Jerry E. Vockley · 2019 · Molecular Genetics and Metabolism
79. Targeting pre-mRNA splicing in cancers: roles, inhibitors, and therapeutic opportunities
    Shinsuke Araki, Momoko Ohori, Masato Yugami · 2023 · Frontiers in Oncology
80. Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor
    Alessandra Feoli, Giulia Iannelli, Alessandra Cipriano, Ciro Milite, Lei Shen, Zhihao Wang, Andrea Hadjikyriacou, Troy L. Lowe, Cyrus Safaeipour, Monica Viviano et al. · 2023 · Journal of Medicinal Chemistry
81. Bioactive atropisomers: Unraveling design strategies and synthetic routes for drug discovery
    Shuai‐Jiang Liu, Qian Zhao, Xiaochen Liu, Allan B. Gamble, Wei Huang, Qian‐Qian Yang, Bo Han · 2024 · Medicinal Research Reviews
82. Glioblastoma and Methionine Addiction
    Mark L. Sowers, Lawrence C. Sowers · 2022 · International Journal of Molecular Sciences
83. An updated patent review of protein arginine N-methyltransferase inhibitors (2019–2022)
    Jinyun Dong, Ji‐Long Duan, Zi Hui, Carmen Garrido, Zhangshuang Deng, Tian Xie, Xiang‐Yang Ye · 2022 · Expert Opinion on Therapeutic Patents
84. The Role of PRMT5 in Immuno-Oncology
    Yoshinori Abe, Takumi Sano, Nobuyuki Tanaka · 2023 · Genes
85. Heat Capacity Changes for Transition-State Analogue Binding and Catalysis with Human 5′-Methylthioadenosine Phosphorylase
    Ross Firestone, Scott A. Cameron, Jerome M. Karp, Vickery L. Arcus, Vern L. Schramm · 2016 · ACS Chemical Biology
86. Cofactors As Metabolic Sensors Driving Cell Adaptation in Physiology and Disease
    Nabil Rabhi, Sarah Anissa Hannou, Philippe Froguel, Jean‐Sébastien Annicotte · 2017 · Frontiers in Endocrinology
87. Cancer epigenetic therapy: recent advances, challenges, and emerging opportunities
    Rajita J. Vatapalli, Alex P. Rossi, Ho Man Chan, Jingwen Zhang · 2024 · Epigenomics
88. A review of the known MTA-cooperative PRMT5 inhibitors
    Mei Long Hu, Xiang Chen · 2024 · RSC Advances
89. Downregulation of MTAP promotes Tumor Growth and Metastasis by regulating ODC Activity in Breast Cancer
    Ying Zhang, Tiantian Zhang, Lin Gao, Yanan Tan, Yuting Li, Xiangyu Tan, Tuxiong Huang, Huahui Li, Feng Bai, Chang Zou et al. · 2022 · International Journal of Biological Sciences
90. PRMT5-regulated splicing of DNA repair genes drives chemoresistance in breast cancer stem cells
    Matthew S. Gillespie, Kelly Chiang, Gemma L. Regan-Mochrie, Soo‐Youn Choi, Ciara M. Ward, Debashish Sahay, Paloma García, Roland R. Arnold, Clare C. Davies · 2024 · Oncogene
91. Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma
    Haoran Mu, Qi Zhang, Dongqing Zuo, Jinzeng Wang, Yining Tao, Zhen Li, Xin He, Huanliang Meng, Hongsheng Wang, Jiakang Shen et al. · 2025 · Cell Reports Medicine
92. A patent review of PRMT5 inhibitors to treat cancer (2018 - present)
    Jing Gao, Jie Yang, Shengyu Xue, Hong Ding, Hua Lin, Cheng Luo · 2023 · Expert Opinion on Therapeutic Patents
93. Targeting the insulin-like growth factor-1 receptor in MTAP-deficient renal cell carcinoma
    Jihao Xu, Wen‐Hsin Chang, Lon Wolf R. Fong, Robert H. Weiss, Sung‐Liang Yu, Ching‐Hsien Chen · 2019 · Signal Transduction and Targeted Therapy
94. From DNA-Encoded Library Screening to AM-9747: An MTA-Cooperative PRMT5 Inhibitor with Potent Oral In Vivo Efficacy
    Ian Sarvary, M. Vestergaard, Loris Moretti, Jan Andersson, Jorge Peiró Cadahía, Sanne Cowland, Thomas Flagstad, Thomas Franch, Alex Haahr Gouliaev, Gitte Husemoen et al. · 2025 · Journal of Medicinal Chemistry
95. Synthetic lethality in cancer drug discovery: challenges and opportunities
    Emanuel Gonçalves, Colm J. Ryan, David J. Adams · 2025 · Nature Reviews Drug Discovery
96. The Oncometabolite 5′-Deoxy-5′-Methylthioadenosine Blocks Multiple Signaling Pathways of NK Cell Activation
    Bénédikt Jacobs, Sebastian Schlögl, Carolin Dorothea Strobl, Simon Völkl, Andrej Stoll, Dimitrios Mougiakakos, Karl‐Johan Malmberg, Andréas Mackensen, Michael Aigner · 2020 · Frontiers in Immunology
97. Pancreatic Cancer Organoids: An Emerging Platform for Precision Medicine?
    Evangelia Sereti, Irida Papapostolou, KONSTANTINOS S. DIMAS · 2023 · Biomedicines
98. Is There a Therapeutic Window for Metabolism-Based Cancer Therapies?
    Sarah‐Maria Fendt · 2017 · Frontiers in Endocrinology
99. The Transition-State Structure for Human MAT2A from Isotope Effects
    Ross Firestone, Vern L. Schramm · 2017 · Journal of the American Chemical Society
100. Specific regulation of epigenome landscape by metabolic enzymes and metabolites
     Xilan Yu, Shanshan Li · 2024 · Biological reviews/Biological reviews of the Cambridge Philosophical Society